SAVA - Alzheimer's-Focused Cassava Sciences Faces Controversy as Key Collaborator Accused of Scientific Misconduct | Benzinga
Cassava Sciences Inc (NASDAQ: SAVA), the Alzheimer-focused firm, is facing further controversy as a recent investigation by the City University of New York (CUNY) has implicated neuroscientist Hoau-Yan Wang, a long-time collaborator of Cassava, in scientific misconduct related to 20 research papers.
These papers were crucial in advancing simufilam, the company's lead Alzheimer's program, from the laboratory to ongoing clinical trials.
The CUNY investigative committee uncovered several instances of improperly manipulated images, particularly in a 2012 publication in The Journal of Neuroscience, which suggested that simufilam could mitigate the pathological effects of beta-amyloid, a protein associated with Alzheimer's disease.
Additionally, the Science report pointed out ...